For research use only. Not for therapeutic Use.
Deruxtecan（Cat No.:I020228）, is an antibody-drug conjugate (ADC) used in cancer therapy. It consists of a monoclonal antibody that selectively targets cancer cells and a cytotoxic payload attached through a linker molecule. Specifically, deruxtecan incorporates the topoisomerase I inhibitor eaten as the cytotoxic agent. This ADC approach allows for targeted delivery of the cytotoxic payload to cancer cells, enhancing its efficacy while minimizing damage to healthy cells. Deruxtecan has shown promising results in clinical trials for the treatment of various cancers, including breast, lung, and gastric cancers.
| Catalog Number | I020228 |
| CAS Number | 1599440-13-7 |
| Molecular Formula | C₅₂H₅₆FN₉O₁₃ |
| Purity | ≥95% |
| Documentation | |
| Target | Drug-Linker Conjugates for ADC |
| Reference | [1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.<br>[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. |
